Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cyclosporine
Drug ID BADD_D00551
Description Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_.[A174049] Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Indications and Usage For treatment of transplant (kidney, liver, and heart) rejection, rheumatoid arthritis, severe psoriasis.
Marketing Status Prescription; Discontinued
ATC Code L04AD01; S01XA18
DrugBank ID DB00091
KEGG ID D00184
MeSH ID D016572
PubChem ID 5280754
TTD Drug ID D0O3YF
NDC Product Code 55486-1604; 55486-1602; 11014-0041; 68084-879; 51927-0160; 59573-0001; 0093-9020; 60505-0133; 60505-4630; 52972-0027; 55486-1603; 55361-0025; 0093-5742; 55361-0022; 55361-0023; 0074-5503; 55361-0026; 10702-808; 0074-3108; 11014-0040; 0093-5740; 10888-5040; 47335-506; 0023-9163; 50090-1242; 68084-921; 0078-0241; 0074-3109; 55500-0009; 0078-0110; 0093-5741; 65897-1008; 10888-5041; 0378-8760; 47335-507; 51552-0663; 0078-0274; 68254-2501; 51862-460; 55486-1567; 65086-001; 0074-7269; 51927-0213; 60505-6202; 11014-0033; 60505-4631; 11014-0034; 60505-0134; 68254-0008; 0574-0866; 0172-7313; 66507-0001; 0078-0240; 50090-4476; 0078-0246; 0078-0248; 0093-9019; 63629-8640; 51927-3196; 0093-9018; 47848-004; 72969-017; 0078-0109; 0023-5301; 60505-4632; 51862-458; 52928-005
Synonyms Cyclosporine | Cyclosporine A | Cyclosporin A | Ciclosporin | Cyclosporin | Neoral | Sandimmun Neoral | CyA-NOF | CyA NOF | Sandimmune | Sandimmun | CsA-Neoral | CsA Neoral | CsANeoral | OL 27-400 | OL 27 400 | OL 27400
Chemical Information
Molecular Formula C62H111N11O12
CAS Registry Number 59865-13-3
SMILES CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C (C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C C(C)C)C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionT-cell surface glycoprotein CD3 epsilon chainA6H6M1Not Available2246324; 2738100; 8880225; 8288727; 2515162; 6831033; 3871216; 1950737; 2548278; 2846698; 3262683; 7759599; 9869836; 2211719; 3131638; 2809200; 2540100; 9287244; 12082550; 7535569
Bladder perforationvon Willebrand factorP04275T233488249125; 9352228; 9414275; 8589211; 9241755; 7544037; 9351387; 7586318; 2470733; 8615807; 11230807
Bone density decreasedParathyroid hormoneP01270T987088864416; 11303710; 9141540; 11012914; 11446565; 9514219; 9933485
Bone density decreasedOsteocalcinP02818Not Available8864416; 11303710; 9141540; 11012914; 11446565; 9514219; 9933485
ComaGamma-aminobutyric acid receptor subunit beta-1P15431Not Available10465348; 15730878; 10686090; 6694095
Complications of transplanted kidneyvon Willebrand factorP04275T233488249125; 9352228; 9414275; 8589211; 9241755; 7544037; 9351387; 7586318; 2470733; 8615807; 11230807
EncephalopathyGamma-aminobutyric acid receptor subunit beta-1P15431Not Available10465348; 15730878; 10686090; 6694095
Haemolysisvon Willebrand factorP04275T233488249125; 9352228; 9414275; 8589211; 9241755; 7544037; 9351387; 7586318; 2470733; 8615807; 11230807
HypertensionEndothelin-1P05305T2507610930191; 9931093; 8986453
HypertensionNitric oxide synthase, endothelialP29474T0604610930191; 9931093; 8986453
HypertensionNeprilysinP08473T0540910930191; 9931093; 8986453
Nephropathy toxicCalcineurin subunit B type 1P63098Not Available8591053; 7694398; 7592869; 7533090; 7542793; 7524531; 7520696
Renal disorderGolgin subfamily A member 2Q08379Not Available9125798; 9987092; 9214404; 12166693; 7564111; 12099512; 12427154
Renal disorderTransforming growth factor beta-1 proproteinP01137T972579125798; 9987092; 9214404; 12166693; 7564111; 12099512; 12427154
SeizureGamma-aminobutyric acid receptor subunit beta-1P15431Not Available10465348; 15730878; 10686090; 6694095
ThrombosisGuanine nucleotide-binding protein G(q) subunit alphaP50148T122901848730; 7878634
ThrombosisThrombomodulinP07204T085831848730; 7878634
TremorGamma-aminobutyric acid receptor subunit beta-1P15431Not Available10465348; 15730878; 10686090; 6694095
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Renal lymphocele24.09.02.008; 20.02.03.016; 12.02.10.010; 01.09.01.0280.000519%Not Available
Sputum retention22.02.03.0120.000135%Not Available
Hyperphosphatasaemia09.01.08.002; 15.02.04.011; 14.11.01.0020.000519%Not Available
Glomerulosclerosis20.05.03.0080.000135%Not Available
Immunosuppressant drug level decreased13.17.01.0310.006230%Not Available
Hypercreatininaemia20.01.02.016; 14.11.01.0390.000519%Not Available
Spondylolisthesis15.10.04.0040.000519%Not Available
Acute lymphocytic leukaemia recurrent16.01.01.003; 01.10.01.0030.000203%Not Available
Graft versus host disease in skin23.07.04.025; 12.02.09.031; 10.02.01.0620.000779%Not Available
Clonal evolution16.32.03.0220.001038%Not Available
Acute graft versus host disease in skin12.02.09.022; 10.02.01.053; 23.07.04.0200.002336%Not Available
Human herpesvirus 8 infection11.05.02.033; 10.03.03.0080.000519%Not Available
Skin plaque23.03.03.0440.001038%Not Available
Cerebral amyloid angiopathy24.03.05.010; 17.08.02.017; 10.02.05.0030.000135%Not Available
Epstein-Barr virus associated lymphoma16.28.01.003; 11.05.10.007; 01.15.01.0030.000135%Not Available
Eyelid skin dryness23.03.03.065; 06.06.04.0200.001038%Not Available
Eyelid thickening23.07.05.007; 06.06.04.0210.000519%Not Available
Meniscus injury15.07.03.006; 12.04.03.0080.001038%Not Available
Graft versus host disease in gastrointestinal tract12.02.09.028; 10.02.01.059; 07.11.01.0270.000271%Not Available
Toxic leukoencephalopathy17.13.02.012; 12.03.01.0590.001038%Not Available
End stage renal disease20.01.03.0190.001558%Not Available
The 29th Page    First    Pre   29    Total 29 Pages